Cipla is currently trading at Rs. 315.75, up by 1.85 points or 0.59% from its previous closing of Rs. 313.90 on the BSE.
The scrip opened at Rs. 312.55 and has touched a high and low of Rs. 316.90 and Rs. 308.50 respectively. So far 18,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 359.00 on 07-Feb-2012 and a 52 week low of Rs. 273.60 on 06-Sep-2011.
Last one week high and low of the scrip stood at Rs. 327.50 and Rs. 308.50 respectively. The current market cap of the company is Rs. 25,352 crore.
The promoters holding in the company stood at 36.80% while Institutions and Non-Institutions held 33.27% and 29.84% respectively.
Drug major Cipla has reported a growth of 36.32% in its net profit to Rs 291.74 crore for the fourth quarter ended March 31, 2012. The company had posted a net profit of Rs 214 crore for the quarter ended March 31, 2011.
The company’s total income stood at Rs 1,865.57 crore for the quarter ended March 31, 2012 as against Rs 1,667.74 crore for the corresponding period previous fiscal, up by 11.86%.
The company’s net profit for the year ended March 31, 2012, rose 17.03% to Rs 1,123.96 crore from Rs 960.39 crore for the year ago period. Total income of the company surged by10.21% to Rs 6,977.50 crore for the year ended March this year from Rs 6,331.09 crore for corresponding period last year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: